Or

Open access

NEWS - Oncology

Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review – JNCI: Journal of the National Cancer Institute (free)

Commentary: Adverse Mental Health Outcomes in Breast Cancer Survivors – The ASCO Post (free)

“There is compelling evidence of an increased risk of anxiety, depression and suicide, and neurocognitive and sexual dysfunctions in breast cancer survivors compared with women with no prior cancer.”

 


Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer – New England Journal of Medicine (free for a limited period)

Commentaries: Not So Fast With Immune Therapy For Breast Cancer – Forbes (free) AND Immunotherapy drugs show some promise against breast cancer – STAT (free)

“…the benefit for most women was small, raising questions about whether the treatment is worth its high cost and side effects.” (from STAT)

 


Are We Being Misled About Precision Medicine? – The New York Times (10 articles per month are free)

“Doctors and hospitals love to talk about the cancer patients they’ve saved, and reporters love to write about them. But deaths still vastly outnumber the rare successes.”

 


Playing Doctor with Watson: Medical Applications Expose Current Limits of AI – Spiegel (free) (via @EricTopol)

“IBM has big plans for how its Watson artificial intelligence software could change the medical industry. But a number of hospitals have ended their experiments with the platform, arguing that it doesn’t help diagnose or treat diseases.”

 


The right diet can boost potency of cancer drugs – Nature News (free)

Original article: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors – Nature (link to abstract – $ for full-text)

Related: Top oncologist to study effect of diet on cancer drugs – The Guardian (free)

“Diets appear to matter in mouse cancer Rx – can these preclinical findings be translated to humans?” (via @Aiims1742 see Tweet)

 


Last Month in Oncology with Dr. Bishal Gyawali: June 2018 – eCancer News (free)

This review has an interesting opinion on changing definitions of clinically meaningful endpoints in cancer research.

 


Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cabozantinib in Hepatocellular Carcinoma – NEJM Resident 360 (free)

Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo, but the rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.


Page 1 of 512345
Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •